Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.

被引：1
|
作者：
Park, Esther
Abu-Khalaf, Maysa M.
Hatzis, Christos
LaSala, Johanna M.
Silber, Andrea
Hofstatter, Erin Wysong
Sanft, Tara Beth
Russell, Raymond
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA
[3] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e11501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11501
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Aromatase inhibitors: Effective endocrine therapy in the early adjuvant setting for postmenopausal women with hormone-responsive breast cancer
    Mauriac, Louis
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 20 : S15 - S29
  • [12] A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer
    Petit, Thierry
    Dufour, Patrick
    Tannock, Ian
    ENDOCRINE-RELATED CANCER, 2011, 18 (03) : R79 - R89
  • [13] A study of adverse vascular effects of adjuvant therapy with aromatase inhibitors in women with breast cancer
    Lindman, H.
    Dahlberg, L.
    Larsson, M.
    Naessen, T.
    CANCER RESEARCH, 2019, 79 (04)
  • [14] Upfront adjuvant aromatase inhibitors in women with lobular breast cancer
    Montemurro, Filippo
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (15) : 3376 - 3377
  • [15] Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer
    Michaud, LB
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (03) : 266 - 273
  • [16] The use of aromatase inhibitors in adjuvant therapy for early breast cancer
    Jonat, W
    Hilpert, F
    Maass, N
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (Suppl 1) : S32 - S38
  • [17] The use of aromatase inhibitors in adjuvant therapy for early breast cancer
    Walter Jonat
    Felix Hilpert
    Nicolai Maass
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 32 - 38
  • [18] Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer
    van de Velde, C. J. H.
    Verma, S.
    van Nes, J. G. H.
    Masterman, C.
    Pritchard, K. I.
    CANCER TREATMENT REVIEWS, 2010, 36 (01) : 54 - 62
  • [19] Endocrine adjuvant therapy in male breast cancer (MBC): tamoxifen (TAM), aromatase inhibitors (AI) or both?
    Cutuli, B.
    Cohen-Solal, C.
    Serin, D.
    Kirova, Y.
    Gaci, Z.
    Lemanski, C.
    De Lafontan, B.
    Zoubir, M.
    Maingon, P.
    Mignotte, H.
    de Lara, Tunon C.
    Edeline, J.
    Penault-Llorca, F.
    Romestaing, P.
    Delva, C.
    Belkacemi, Y.
    CANCER RESEARCH, 2009, 69 (02) : 290S - 290S
  • [20] Adjuvant aromatase inhibitors for breast cancer
    Howell, A
    LANCET, 2005, 366 (9484): : 431 - 433
12345